CL2023002992A1 - Anticuerpos anti-c-met y conjugados de anticuerpo-fármaco - Google Patents

Anticuerpos anti-c-met y conjugados de anticuerpo-fármaco

Info

Publication number
CL2023002992A1
CL2023002992A1 CL2023002992A CL2023002992A CL2023002992A1 CL 2023002992 A1 CL2023002992 A1 CL 2023002992A1 CL 2023002992 A CL2023002992 A CL 2023002992A CL 2023002992 A CL2023002992 A CL 2023002992A CL 2023002992 A1 CL2023002992 A1 CL 2023002992A1
Authority
CL
Chile
Prior art keywords
antibody
drug conjugates
antibodies
met antibodies
antigen
Prior art date
Application number
CL2023002992A
Other languages
English (en)
Spanish (es)
Inventor
Blomenröhr Marion
Maria Cornelia Van Der Lee Miranda
Gerhard Groothuis Patrick
Original Assignee
Byondis Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Byondis Bv filed Critical Byondis Bv
Publication of CL2023002992A1 publication Critical patent/CL2023002992A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CL2023002992A 2021-04-08 2023-10-05 Anticuerpos anti-c-met y conjugados de anticuerpo-fármaco CL2023002992A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP21167423 2021-04-08

Publications (1)

Publication Number Publication Date
CL2023002992A1 true CL2023002992A1 (es) 2024-04-19

Family

ID=75438640

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2023002992A CL2023002992A1 (es) 2021-04-08 2023-10-05 Anticuerpos anti-c-met y conjugados de anticuerpo-fármaco

Country Status (12)

Country Link
US (1) US20240376214A1 (https=)
EP (1) EP4320152A1 (https=)
JP (1) JP2024515266A (https=)
KR (1) KR20230166099A (https=)
CN (1) CN117157325A (https=)
AU (1) AU2022254291A1 (https=)
BR (1) BR112023020801A2 (https=)
CA (1) CA3214718A1 (https=)
CL (1) CL2023002992A1 (https=)
IL (1) IL306142A (https=)
MX (1) MX2023011929A (https=)
WO (1) WO2022214517A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024108193A2 (en) * 2022-11-18 2024-05-23 Epibiologics, Inc. Degradation of cmet using a bispecific binding agent
WO2024131835A1 (en) * 2022-12-20 2024-06-27 Hansoh Bio Llc Ligand-cytotoxicity drug conjugates and pharmaceutical uses thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2575402A1 (en) 2004-08-05 2006-02-09 Genentech, Inc. Humanized anti-cmet antagonists
PA8849001A1 (es) 2008-11-21 2010-06-28 Lilly Co Eli Anticuerpos de c-met
AR074439A1 (es) * 2008-12-02 2011-01-19 Pf Medicament Anticuerpo anti-cmet (receptor c-met)
PT3056203T (pt) 2010-04-21 2018-02-15 Syntarga Bv Conjugados de análogos de cc-1065 e ligantes bifuncionais
RU2608644C2 (ru) 2010-11-03 2017-01-23 арДЖЕН-ИКС Н.В. Антитела против белка рецептора с-мет
US20140154251A1 (en) 2011-10-05 2014-06-05 Samsung Electronics Co., Ltd. Anti c-met antibody and uses thereof
KR101463098B1 (ko) * 2011-11-28 2014-11-27 한국생명공학연구원 ｃ-Ｍｅｔ에 대한 인간항체에 약물이 접합된 약물 복합체 및 이의 용도
KR102150616B1 (ko) * 2013-09-12 2020-09-03 삼성전자주식회사 c-Met 표적 화합물-생체활성 물질 접합체 및 그 용도
SG11201609372UA (en) 2014-05-22 2016-12-29 Synthon Biopharmaceuticals Bv Site-specific conjugation of linker drugs to antibodies and resulting adcs
ES2748295T3 (es) 2014-09-16 2020-03-16 Symphogen As Anticuerpos anti-MET y composiciones
WO2016165580A1 (zh) * 2015-04-17 2016-10-20 江苏恒瑞医药股份有限公司 抗c-Met抗体和抗c-Met抗体-细胞毒性药物偶联物及其医药用途
PL3319597T3 (pl) * 2015-07-10 2021-10-11 Byondis B.V. Kompozycje zawierające koniugaty przeciwciało-duokarmycyna
CA3026139C (en) 2016-02-12 2023-09-12 Synthon Biopharmaceuticals B.V. Selective reduction of cysteine-engineered antibodies
SI3626273T1 (sl) 2016-05-17 2021-04-30 Abbvie Biotherapeutics Inc. Konjugati protitelesa proti CMET in zdravila ter postopki za njihovo uporabo
GB201611123D0 (en) 2016-06-27 2016-08-10 Euremab Srl Anti met antibodiesand uses thereof
HUE054571T2 (hu) * 2016-09-14 2021-09-28 Merck Patent Gmbh Hatékony tumorgátlásra szolgáló C-MET elleni ellenanyagok és ellenanyag-drog konjugátumaik
US11419944B2 (en) 2016-10-11 2022-08-23 Byondis B.V. Non-linear self-immolative linkers and conjugates thereof
TWI782930B (zh) * 2016-11-16 2022-11-11 美商再生元醫藥公司 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法
HRP20210922T1 (hr) * 2016-11-23 2021-09-03 Eli Lilly And Company Konjugati protutijela protiv met s lijekom
US20180230218A1 (en) * 2017-01-04 2018-08-16 Immunogen, Inc. Met antibodies and immunoconjugates and uses thereof
US11696958B2 (en) 2017-05-23 2023-07-11 Byondis B.V. Dual conjugation process for preparing antibody-drug conjugates
JP7325339B2 (ja) * 2017-05-30 2023-08-14 チョン クン ダン ファーマシューティカル コーポレーション 新規な抗ｃ－Ｍｅｔ抗体およびその用途
EP3774923A4 (en) * 2018-03-28 2021-12-29 Mitsubishi Tanabe Pharma Corporation Drug conjugates of cmet monoclonal binding agents, and uses thereof

Also Published As

Publication number Publication date
IL306142A (en) 2023-11-01
BR112023020801A2 (pt) 2023-12-12
WO2022214517A1 (en) 2022-10-13
CA3214718A1 (en) 2022-10-13
AU2022254291A1 (en) 2023-10-12
KR20230166099A (ko) 2023-12-06
AU2022254291A9 (en) 2024-02-22
CN117157325A (zh) 2023-12-01
EP4320152A1 (en) 2024-02-14
JP2024515266A (ja) 2024-04-08
MX2023011929A (es) 2023-10-23
US20240376214A1 (en) 2024-11-14

Similar Documents

Publication Publication Date Title
AR122546A1 (es) Conjugados de anticuerpo anti bcma-fármaco y métodos de uso
MX2020007077A (es) Anticuerpos anti-factor tisular, conjugados anticuerpo-farmaco y metodos relacionados.
CL2023002992A1 (es) Anticuerpos anti-c-met y conjugados de anticuerpo-fármaco
BR112022008756A2 (pt) Conjugados anticorpo-fármaco anti-mesotelina eribulina e métodos de uso
CL2024003094A1 (es) Conjugados de anticuerpos y fármacos anti-factor tisular y métodos relacionados.
CL2025001913A1 (es) Anticuerpo anti-nectina-4; conjugado que lo comprende; composición farmacéutica; y su uso.
MX2023012848A (es) Conjugados de anticuerpo-farmaco anti-c-met.
CL2021001607A1 (es) Anticuerpos anti-pmel17 y conjugados de los mismos
CO2024012877A2 (es) Conjugados de fármaco-anticuerpo dirigidos al receptor de folato alfa y métodos de uso
MX2022006289A (es) Tratamiento de canceres con conjugados anticuerpo-farmaco (adc) que se unen a las proteinas 191p4d12.
MX2025000550A (es) Conjugados anticuerpo-fármaco que se unen a la proteína 1 que contiene el dominio cub (cdcp1) y usos de los mismos
ECSP20020949A (es) Conjugados de fármaco-anticuerpo (adc) anti-egfr y sus usos
CO2025003362A2 (es) Conjugados de fármacos anticuerpo anti-sez6
MX2024008174A (es) Metodos para tratar el cancer urotelial musculo-invasivo o el cancer de vejiga musculo-invasivo con conjugados anticuerpo-farmaco (adc) que se unen a las proteinas 191p4d12
MX2021010254A (es) Conjugados de anticuerpo-farmaco que comprenden anticuerpos anti-tm4sf1 y metodos de uso de los mismos.
CO2025002301A2 (es) Anticuerpos anti-ccr8 y métodos de uso
CL2023003905A1 (es) Conjugados novedosos que comprenden fosfoantígenos y su uso terapéutico
MX2023014683A (es) Conjugados de anticuerpo anti-egfrviii y farmaco y usos de los mismos.
PY2231960A (es) Composición farmacéutica de pembrolizumab y su uso
BR112019002213A2 (pt) composições e o uso das mesmas para tratar ou prevenir rosácea
AR120550A1 (es) Tratamiento para cáncer con conjugados de anticuerpo-fármaco (adc) que se unen a proteínas de 191p4d12
AR122660A2 (es) Anticuerpos anti-pmel17 y conjugados de los mismos
CO2025006994A2 (es) Anticuerpos anti–cd137 y métodos de uso
DOP2024000176A (es) Molécula de unión dirigida a ror1 y uso de la misma
MX2022008745A (es) Anticuerpos anti-nkp30 y metodos de uso.